{"id":"NCT04408794","sponsor":"Pfizer","briefTitle":"Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine","officialTitle":"A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (Zavegepant*) Intranasal (IN) for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-06-29","primaryCompletion":"2021-12-09","completion":"2021-12-23","firstPosted":"2020-05-29","resultsPosted":"2023-03-16","lastUpdate":"2023-05-18"},"enrollment":974,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Migraine"],"interventions":[{"type":"DRUG","name":"Zavegepant (BHV-3500)","otherNames":["Vazegepant"]}],"arms":[{"label":"Zavegepant (BHV-3500)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine.\n\n\\* BHV-3500, formerly \"vazegepant\", is now referred to as \"zavegepant\" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to \"zavegepant\" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.","primaryOutcome":{"measure":"Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation","timeFrame":"From study drug dosing up to the end of the study (up to 52 weeks)","effectByArm":[{"arm":"Zavegepant 10 mg","deltaMin":460,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":67,"countries":["United States"]},"refs":{"pmids":["39210835"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":603},"commonTop":["Dysgeusia","Nasal discomfort","COVID-19","Nausea","Nasal congestion"]}}